rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12...4567891011121314...1617»
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Novel Sulfonamide-Based Carbamates as Selective Inhibitors of BChE. (Pubmed Central) -  Oct 30, 2021   
    Except for three compounds, all compounds showed strong preferential inhibition of BChE, and nine compounds were even more active than the clinically used rivastigmine...The detailed information about the mode of binding of these compounds to the active site of both BChE and AChE was obtained in a molecular modeling study. In this study, combined techniques (docking, molecular dynamic simulations, and QTAIM (quantum theory of atoms in molecules) calculations) were employed.
  • ||||||||||  amantadine / Generic mfg.
    Review, Journal:  Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update. (Pubmed Central) -  Oct 22, 2021   
    Long-acting formulations of amantadine are approved for treating dyskinesia...For example, CX-8998 (a calcium channel modulator) is being evaluated for PD tremor and rivastigmine may improve gait dysfunction in PD. Drug repurposing continues to be a key strategy for non-dopaminergic targets in PD, but the field needs to increase discovery and availability of such drugs.
  • ||||||||||  rivastigmine / Generic mfg.
    Clinical, Journal:  Evaluation of rivastigmine in Alzheimer's disease. (Pubmed Central) -  Oct 16, 2021   
    Its availability as both a transdermal formulation and oral capsule, may improve adherence rates and care giver satisfaction compared with other ChEIs. To date, the data from randomized clinical trials and post marketing observational studies have shown evidence for an impact on cognitive functions in AD with good safety and tolerability.
  • ||||||||||  rivastigmine / Generic mfg.
    Review, Journal:  Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy. (Pubmed Central) -  Sep 30, 2021   
    Natural inhibitors of acetylcholine (ACh) such as galanthamine and rivastigmine are used commercially in the treatmentof AD...Sesquiterpene is an important category of terpenoids, found to possess a large spectrum of biological activities. The outcome of the review clearly states that sesquiterpenes (such as amberboin, lipidiol,etc) from herbs could offer fresh, functional compounds for possible prevention and treatment of AD.
  • ||||||||||  ropinirole IR / Generic mfg., paroxetine / Generic mfg., rivastigmine / Generic mfg.
    [VIRTUAL] Unusual Progressive Supranuclear Palsy: a case report () -  Sep 29, 2021 - Abstract #MDSCongress2021MDS_Congress_870;    
    We then added ropinirole, rivastigmine and paroxetine. The onset of PSP after the age of 40 is one of the diagnostic requirements so far, however, early presentations should be considered.
  • ||||||||||  Aduhelm (aducanumab) / Eisai, Biogen
    Journal:  Aducanumab (Aduhelm) for Alzheimer's disease. (Pubmed Central) -  Sep 29, 2021   
    The onset of PSP after the age of 40 is one of the diagnostic requirements so far, however, early presentations should be considered. No abstract available
  • ||||||||||  rivastigmine / Generic mfg.
    Enrollment open:  Toward a Computationally-Informed, Personalized Treatment for Hallucinations (clinicaltrials.gov) -  Sep 17, 2021   
    P1,  N=35, Recruiting, 
    The limited data of the study favor a wait and see approach instead of early treatment with rivastigmine in PD patients with minor VH. Not yet recruiting --> Recruiting
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Novel chrysin derivatives as hidden multifunctional agents for anti-Alzheimer's disease: design, synthesis and in vitro evaluation. (Pubmed Central) -  Sep 17, 2021   
    In this study, the 'hidden' multi-target strategy was used in combination with chrysin's metal chelating site and rivastigmine's anti-cholinesterase pharmacophore to form an ester, which improves the hydrophobicity and protects the phenolic hydroxyl group at the same time...At the same time, phenol fragment can exert its good antioxidant effect. Overall, these findings demonstrated that compound 3 might be considered as a potential hidden multifunctional candidate in the therapy of AD.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signaling. (Pubmed Central) -  Sep 15, 2021   
    Rivastigmine treatment significantly enhances the proteasome activity and may contributes in removal of amyloid aggregation. In conclusion, findings suggested that along with inhibitory effect of rivastigmine on acetylcholinesterase activity and up to some extent on cognition, it has significant effect on disease related biochemical alterations, ER functionality, protein degradation machinery and neuronal apoptosis.
  • ||||||||||  rivastigmine / Generic mfg.
    Journal:  Synthesis and characterization of a novel molecularly imprinted polymer for the controlled release of rivastigmine tartrate. (Pubmed Central) -  Sep 11, 2021   
    Studies pertaining to the in-vitro release of RVS from MIP2 samples showed that the prepared sample had a controlled and sustained release compared, which differed from the results obtained from the non-imprinted polymer (NIP) with the same formulization. Results obtained further reinforced the feasibility of prepared MIPs as a prime candidature for RVS drug delivery to alleviate Alzheimer's and other diseases.
  • ||||||||||  galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Journal:  Transdermal drug delivery systems and their potential on Alzheimer's disease management. (Pubmed Central) -  Sep 5, 2021   
    Results obtained further reinforced the feasibility of prepared MIPs as a prime candidature for RVS drug delivery to alleviate Alzheimer's and other diseases. In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated.
  • ||||||||||  rivastigmine / Generic mfg.
    Trial completion date, Trial primary completion date:  RIVA-PSP: Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (clinicaltrials.gov) -  Aug 18, 2021   
    P3,  N=106, Recruiting, 
    In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated. Trial completion date: Nov 2019 --> Aug 2022 | Trial primary completion date: Jul 2019 --> Dec 2021
  • ||||||||||  rivastigmine / Generic mfg., duloxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Quality Improvement and Practice Based Research in Neurology Using the EMR (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=3300, Enrolling by invitation, 
    Trial completion date: Nov 2019 --> Aug 2022 | Trial primary completion date: Jul 2019 --> Dec 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase. (Pubmed Central) -  Aug 13, 2021   
    In this review we summarize the studies reporting phytocompounds and extracts from medicinal plants that show AChE inhibitory activities and could be of potential benefit in AD. Future research directions are suggested and recommendations made to expand the use of medicinal plants and their formulations to prevent, mitigate and treat AD.
  • ||||||||||  methylphenidate tablet / Generic mfg.
    Journal, Adverse drug reaction:  Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands. (Pubmed Central) -  Aug 8, 2021   
    We also demonstrate similar results when using the user-corrected number of ADRs instead of the switch-corrected number of ADRs, allowing for a more feasible approach in pharmacovigilance practice. This study demonstrates that pharmacovigilance analyses of switch-related ADRs leads to different results when the number of reported ADRs is corrected for the actual number of drug switches.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets. (Pubmed Central) -  Aug 6, 2021   
    On the other hand, memantine is the only non-competitive NMDAR antagonist approved in AD treatment...This review focus on the significance of privileged scaffolds in the generation of the multi-target lead compound for treating AD, investigating the idea and challenges of multi-target drug design. Furthermore, the most auspicious elementary units for designing as well as synthesizing hybrid drugs are demonstrated as pharmacological probes in the rational design of new potential AD therapeutics.
  • ||||||||||  rivastigmine / Generic mfg.
    Preclinical, Journal:  Acetylcholinesterase inhibition in electric eel and human donor blood: an in vitro approach to investigate interspecies differences and human variability in toxicodynamics. (Pubmed Central) -  Aug 5, 2021   
    Electric eel enzyme and human blood of 20 different donors (12 men/8 women) were exposed to eight different compounds (chlorpyrifos, chlorpyrifos-oxon, phosmet, phosmet-oxon, diazinon, diazinon-oxon, pirimicarb, rivastigmine) and inhibition of AChE was measured using the Ellman method...This study provides a reliable in vitro method for assessing human variability in AChE toxicodynamics. The data suggest that the default uncertainty factor of ~ 3.16 may overestimate human variability for this toxicity endpoint, implying that specific toxicodynamic-related adjustment factors can support quantitative in vitro to in vivo extrapolations that link kinetic and dynamic data to improve chemical risk assessment.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Masitinib in mild to moderate Alzheimer’s disease: Results from study AB09004 (Convention Ctr - Four Seasons Ballroom 1) -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1821;    
    Eligible patients that had a clinical diagnosis of AD with baseline mini-mental state examination (MMSE) score ≥12–≤25, and had received a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine for ≥6 months, were treated for 24 weeks. Masitinib (4.5mg/kg/day), a tyrosine kinase inhibitor targeting mast cell and microglia activity, may provide a new treatment option for mild to moderate AD.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Dementia care in diverse older adults in the Deep South and the rest of the US () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1094;    
    ADRD specialist and drug utilization is relatively low in both DS and non-DS, with no significant R/E differences. Research should continue to examine factors that may drive medical care decisions of older adults with ADRD in US regions with different socio-economic and medical resource contexts.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Care Processes Related to Clinical Detection of Alzheimer’s Disease in the US Veterans Affairs Healthcare System () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_947;    
    Prior to the first ICD coding, 53.1% received codes for non-specific dementia and 29.4% for mild cognitive impairment (MCI), with the first code appearing an average of 3 years before the first AD code. In the year before the first AD code, 51.1% visited specialists, 25.7% received neuropsychological assessments, 31.3% had brain imaging (but only 1.3% had a fluorodeoxyglucose-PET scan), 30.2% received prescriptions for dementia medication, 45.8% received community-based services, and 15.0% were admitted to institutional long-term care.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg.
    Review, Journal:  The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease. (Pubmed Central) -  Jul 22, 2021   
    The purpose of this review is to provide an overview of what has been published over the last decade on the effectiveness of AChEIs in AD, analysing the most relevant issues under the clinical and methodological profiles and the consequent possible welfare effects for the whole world. Furthermore, novel drugs and possible therapeutic approaches are also discussed.
  • ||||||||||  rivastigmine / Generic mfg.
    Trial initiation date:  Telerehabilitation Alzheimer's Disease Feasibility (TADF) (clinicaltrials.gov) -  Jul 19, 2021   
    P=N/A,  N=14, Not yet recruiting, 
    Furthermore, novel drugs and possible therapeutic approaches are also discussed. Initiation date: Apr 2021 --> Sep 2021